A 4-Week Dose-Ranging and Efficacy Trial of KRX-0502 (Ferric Citrate) in Patients With End-Stage Renal Disease

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 154 participants.

Also called NCT01074125

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 154 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01074125
Other papers using this trial's data
  • Dose-response and efficacy of ferric citrate to treat hyperphosphatemia in hemodialysis patients: a short-term randomized trial American journal of kidney diseases : the official journal of the National Kidney Foundation, 2013-05 DOI, PubMed 23369827

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Puerto Rico (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01074125. Randomized; no masking; primary purpose treatment. Start 2010-05 (registry gives no type); primary completion 2010-11 (actual). Results posted on 2014-12-04.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A 4-Week Dose-Ranging and Efficacy Trial of KRX-0502 (Ferric Citrate) in Patients With End-Stage Renal Disease
Condition
Hyperphosphatemia
Condition
End-Stage Renal Disease
Intervention (Drug)
ferric citrate
Lead sponsor
Keryx Biopharmaceuticals (class: industry)
Collaborator
Collaborative Study Group (CSG) (class: research network)

Record details

Record id
cardio:ct-nct01074125
Content hash
a75de514071f4543d203fbd74c5c786c666043ec633a796b9fc4aefe484046e6